Supn stock zacks
Get today's Supernus Pharmaceuticals Inc stock price and latest SUPN news as well as Supernus real-time stock quotes, technical analysis, full financials and more. Zacks Equity Research - ZACKS - Tue Nov 5, 5:45PM CST Supernus (SUPN) delivered earnings and revenue surprises of -8.47% and -6.51%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock? Zacks Investment Research downgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN) from a hold rating to a strong sell rating in a research note released on Wednesday, Zacks.com reports. According to Zacks, “Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. 8/7/2019 · Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Supernus Pharmaceuticals, Inc. (SUPN) : Free Stock Analysis Report
Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.
The S&P Pharmaceuticals Select Industry Index (SPSIPHTR) is a modified equal-weighted index that is designed to measure performance of the stocks 6 days ago Six analysts have rated the stock with a hold recommendation and five Zacks Investment Research upgraded Supernus Pharmaceuticals 4 days ago Zacks' sales averages are a mean average based on a survey of CRA International stock traded down $0.08 during trading hours on Friday, 27 Dec 2019 This availability information regarding shortable stocks is indicative only and is CZA, USD, INVESCO ZACKS MID-CAP ETF, Log In to Check Availability SUPN, USD, SUPERNUS PHARMACEUTICALS INC, Log In to
1/1/2020 · Stock analysis for Supernus Pharmaceuticals Inc (SUPN:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company
12 Dec 2019 Orange (NYSE:ORAN) was downgraded by stock analysts at Bryan, Garnier & Co Zacks Investment Research upgraded shares of Orange […]
8/16/2019 · Supernus Pharmaceuticals (NASDAQ:SUPN) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Friday, Zacks.com reports.
8/16/2019 · Supernus Pharmaceuticals (NASDAQ:SUPN) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Friday, Zacks.com reports. Close price at the end of the last trading day (Monday, 16th Dec 2019) of the SUPN stock was $22.82. This is 2.19% more than the trading day before Friday, 13th Dec 2019. Company profile for Supernus Pharm (SUPN) including business summary, key statistics, ratios, sector. SUPN Stock News and Research Articles - Supernus Pharmaceuticals : latest news, headlines and research articles.
4 Payment Stocks to Gain From Strong Online Sales Growth Zacks21 hours ago CHK, FCEL, SUPN and PAYS among midday movers Seeking AlphaNov 06,
8/16/2019 · Supernus Pharmaceuticals (NASDAQ:SUPN) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Friday, Zacks.com reports. Close price at the end of the last trading day (Monday, 16th Dec 2019) of the SUPN stock was $22.82. This is 2.19% more than the trading day before Friday, 13th Dec 2019. Company profile for Supernus Pharm (SUPN) including business summary, key statistics, ratios, sector. SUPN Stock News and Research Articles - Supernus Pharmaceuticals : latest news, headlines and research articles. The latest closing stock price for Supernus Pharmaceuticals as of December 23, 2019 is 24.01. The all-time high Supernus Pharmaceuticals stock closing price was 59.85 on June 29, 2018. The Supernus Pharmaceuticals 52-week high stock price is 43.05, which is 79.3% above the current share price.
We use big data and artificial intelligence to forecast the stock price of Supernus Pharmaceuticals Inc - SUPN. Our stock price predictions cover a period of 3 months. We cover the US equity market. Supernus Pharmaceuticals Inc (Nasdaq:SUPN) was the recipient of a large increase in short interest in the month of December. Learn how to find stocks with unusual options activity. Use MarketBeat's free options scanner to view stocks with unusual call volume activity on the most recent trading day.